

Peptide Therapeutics to Prevent Allergic Reactions to Peanuts Pharmaceutical Ingredients

Fields of use

Dietary. Medical.
Pharmaceutical.

Current state of technology

Laboratory test

Intellectual property

Patent application
submitted,
number: PCT/EP2018/064
063

Developed by Faculty of
Pharmacy, University of
Ljubljana and University
Clinic Golnik

Internal reference.: 821-
3/2017

Contact

[Knowledge transfer office](#)
[UL](#)

Tel: +386 1 24 18 533

E-mail: [gospodarstvo@uni-
lj.si](mailto:gospodarstvo@uni-lj.si)



Background.

Food allergies, in particular, allergy to peanuts, are a serious public health concern that can culminate in death. There are more than 150 million people affected by allergic disease in Europe and 7 million of them suffer from food allergy. This 150 million figure is predicted to increase exponentially and it is estimated that by 2025 more than 50% of all Europeans will suffer from at least one type of allergy, with no age, social or geographical distinction.

Description of the solution.

Type I allergy is characterized by the production of immunoglobulin E (IgE) antibodies, against otherwise harmless antigens. Our novel peanut allergy therapy constitutes of IgE epitope-like peptides, that bind to specific IgEs and Ara h 2- specific IgEs on the surface of effector cells of patients with allergy to peanuts. Consequently, degranulation and segregation of mediators in the allergic reaction are prevented.

Main advantage.

Currently, there is no definitive treatment for peanut allergy. The therapy provides a permanent cure.

Offer of cooperation:

University of Ljubljana is looking for partners for further development of the technology. Available for licencing.